Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
871.60B
Market cap871.60B
Price-Earnings ratio
40.50
Price-Earnings ratio40.50
Dividend yield
0.67%
Dividend yield0.67%
Average volume
2.84M
Average volume2.84M
High today
$939.93
High today$939.93
Low today
$917.02
Low today$917.02
Open price
$929.08
Open price$929.08
Volume
2.35M
Volume2.35M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 871.6B, Eli Lilly(LLY) trades at $929.78. The stock has a price-to-earnings ratio of 40.50 and currently yields dividends of 67.0%.

During the trading session on 2026-04-14, Eli Lilly(LLY) shares reached a daily high of $939.93 and a low of $917.02. At a current price of $929.78, the stock is +1.4% higher than the low and still -1.1% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 2.35M, versus its average volume of 2.84M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

LLY News

The Motley Fool 3h
Could AbbVie Crash Lilly's Weight‑Loss Party?

AbbVie's (ABBV +0.66%) most important therapeutic area has historically been immunology, where it has marketed billion-dollar drugs like Humira, which was once...

Could AbbVie Crash Lilly's Weight‑Loss Party?
Nasdaq 4h
Broker Darlings of the Dow: Johnson & Johnson Ranks As a Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Johnson & Johnson (Symbol: JNJ) is the #10 broker pick, on average, out of the 30 stocks m...

Broker Darlings of the Dow: Johnson & Johnson Ranks As a Top 15 Analyst Pick
Seeking Alpha 8h
Eli Lilly to boost oncology pipeline with CrossBridge Bio buyout

CrossBridge Bio, a privately held biotech focused on developing cancer drugs, announced on Tuesday an agreement to be acquired by Eli Lilly (LLY) in an all-cash...

Eli Lilly to boost oncology pipeline with CrossBridge Bio buyout

Analyst ratings

83%

of 35 ratings
Buy
82.9%
Hold
14.3%
Sell
2.9%

More LLY News

Zacks 10h
The Zacks Analyst Blog Highlights Eli Lilly, Mastercard, Advanced Micro Devices and Stratus Properties

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All...

The Zacks Analyst Blog Highlights Eli Lilly, Mastercard, Advanced Micro Devices and Stratus Properties
Simply Wall St 12h
Jaypirca Trial Win Highlights Eli Lilly’s Expanding Oncology Growth Story

Eli Lilly's Jaypirca (pirtobrutinib) achieved positive Phase 3 results in chronic lymphocytic leukemia and small lymphocytic lymphoma. The late stage trial sho...

Jaypirca Trial Win Highlights Eli Lilly’s Expanding Oncology Growth Story
TipRanks 13h
Novo Nordisk Partners with OpenAI — Is Eli Lilly the Real Target?

Denmark-based Novo Nordisk (NVO) is expanding beyond blockbuster drugs like Wegovy with a new partnership with OpenAI. The collaboration aims to use AI to speed...

TipRanks 1d
Eli Lilly Stock Gets Shot in the Arm from New Leukemia Drug

Eli Lilly (LLY) announced that it has made significant progress with a new leukemia drug, giving its stock a shot in the arm as a result. Unlock hedge fund-lev...

Nasdaq 1d
After Obtaining Approval for Its Weight Loss Pill, Is It Off to the Races for Eli Lilly Stock?

Key Points A weight loss pill would help Eli Lilly reach a broader segment of the population. Its existing GLP-1 drugs have already been generating billions i...

After Obtaining Approval for Its Weight Loss Pill, Is It Off to the Races for Eli Lilly Stock?
Benzinga 1d
Eli Lilly's Jaypirca Builds Case With Fourth Positive Phase 3 Trial In Blood Cancer Patients

Eli Lilly and Co. (NYSE:LLY) shares were little changed in Monday’s premarket session. The U.S. drug giant shared results from the Phase 3 BRUIN CLL-322 trial...

Eli Lilly's Jaypirca Builds Case With Fourth Positive Phase 3 Trial In Blood Cancer Patients
TipRanks 1d
Eli Lilly announces BRUIN CLL-322 trial met primary endpoint

Eli Lilly (LLY) announced topline results from the Phase 3 BRUIN CLL-322 trial of Jaypirca, a non-covalent Bruton tyrosine kinase inhibitor, plus venetoclax and...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.